Table 3.
Patient Characteristics by Time Period and Expenditure Groups
| Early Follow-up | Later Follow-up | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Expenditure Groups | Expenditure Groups | |||||||||
| 0 | low | med | high | P value | 0 | low | med | high | P value | |
| N | 377 | 586 | 586 | 605 | 264 | 557 | 557 | 575 | ||
| Age Category | ||||||||||
| 66 to 69 | 18.8 | 14.8 | 20.2 | 20.7 | 0.1423 | 18.5 | 19.1 | 19.4 | 18.9 | 0.413 |
| 70 to 74 | 26 | 31 | 26.4 | 28.8 | 24.3 | 29.6 | 28.9 | 30.7 | ||
| 75 to 79 | 29.4 | 26.9 | 29 | 28.2 | 28.6 | 26.6 | 30.9 | 26.4 | ||
| 80+ | 25.7 | 27.3 | 24.4 | 22.3 | 28.6 | 24.7 | 20.8 | 24 | ||
| Race | ||||||||||
| White | 91.8 | 95.6 | 90.7 | 90.4 | 0.003 | 88.9 | 94.2 | 92.6 | 91.6 | 0.09 |
| Non-White | 8.2 | 4.4 | 9.3 | 9.6 | 11.1 | 5.8 | 7.4 | 8.4 | ||
| Sex Male | 65.3 | 69.9 | 66.7 | 63.3 | 0.118 | 64 | 69.1 | 70.4 | 62.3 | 0.012 |
| Married | 62.9 | 66.3 | 67.3 | 67.9 | 0.452 | 66.1 | 68.2 | 67.1 | 66 | 0.991 |
| Unmarried/Unknown | 37.1 | 33.7 | 32.7 | 32.1 | 33.9 | 31.8 | 32.9 | 34 | ||
| Grade | ||||||||||
| Well differentiated | <5 | <5 | <5 | <5 | 0.0002 | <5 | <5 | <5 | <5 | 0.0001 |
| Moderately differentiated | 11.4 | 16.4 | 13.6 | 10.2 | 7.4 | 17.2 | 15.4 | 9.8 | ||
| Poorly differentiated | 54.4 | 54 | 47.9 | 49.8 | 57.7 | 49 | 51.7 | 48 | ||
| undifferentiated | 28.4 | 24.5 | 31.5 | 36.4 | 31.2 | 26.6 | 27.3 | 37.9 | ||
| Undetermined | <5 | <5 | <5 | <5 | <5 | <5 | <5 | <5 | ||
| Comorbidity | ||||||||||
| 0 | 56.8 | 54 | 57.4 | 53.9 | 0.6221 | 56.1 | 61 | 55.2 | 53.2 | 0.1319 |
| 1 | 27.8 | 314 | 26.7 | 28 | 25.9 | 26 | 28.1 | 30.7 | ||
| 2 | 11.7 | 10.2 | 10.8 | 12.3 | 12.2 | 9.4 | 12.5 | 10.1 | ||
| 3 | 3.7 | 4.4 | 5.1 | 5.8 | 5.8 | 3.6 | 4.2 | 6 | ||
| Nodes | ||||||||||
| All nodes neg | 33.7 | 37.7 | 35 | 32.9 | 0.0001 | 23.3 | 37.1 | 37.8 | 35.7 | 0.0001 |
| Nodes Positive | 10.3 | 3.9 | 11.1 | 18.8 | 16.4 | 4.3 | 8.4 | 16.1 | ||
| No nodes exam | 56 | 58.4 | 53.9 | 48.3 | 60.3 | 58.6 | 53.8 | 48.2 | ||
| Final Stage | ||||||||||
| Stage 1 | 23.9 | 27.8 | 24.5 | 19.5 | 0.0001 | 18 | 29.2 | 26.2 | 21.1 | 0.0001 |
| Stage 2 | 16.2 | 21.6 | 19.6 | 16 | 13.2 | 20.5 | 18.1 | 21.8 | ||
| Stage 3 | 20.1 | 18.4 | 21.6 | 25.9 | 25.9 | 19.2 | 22.6 | 22.3 | ||
| Stage 4 | 19.6 | 10.6 | 17.2 | 25.4 | 25.9 | 9.1 | 15.5 | 21.3 | ||
| Unknown, No Cancer, In Situ | 20.2 | 21.6 | 17.1 | 13.2 | 17.0 | 22.0 | 17.6 | 13.5 | ||
| Educational Achievement | ||||||||||
| <10 no HS | 32.7 | 29.4 | 30.2 | 32.6 | 0.4262 | 35.8 | 31.3 | 28.5 | 33.5 | 0.1471 |
| 10–19 | 41.8 | 47.1 | 44.5 | 43 | 36.4 | 46.8 | 46 | 42.9 | ||
| 20–29 | 13.4 | 15.6 | 14.8 | 13.4 | 13.9 | 12.6 | 15.7 | 14.6 | ||
| >=30 no HS | 12.1 | 7.9 | 10.5 | 10.9 | 13.9 | 9.3 | 9.8 | 9 | ||
| Readmission | ||||||||||
| None | 16.7 | 15.2 | 12.9 | 14.9 | 0.0414 | 16.4 | 16.5 | 14.5 | 12.7 | 0.004 |
| 1 | 23.6 | 16.3 | 20.2 | 17.2 | 22.2 | 15.6 | 17.6 | 21.3 | ||
| 2 | 15.4 | 15.2 | 15.8 | 18.9 | 18.5 | 12.4 | 14.2 | 18 | ||
| 3+ | 44.3 | 53.3 | 51.1 | 49 | 42.9 | 55.5 | 53.7 | 48 | ||
| Median Income | ||||||||||
| 1st QR | 29.7 | 24.8 | 23.8 | 22 | 0.004 | 29.4 | 24.7 | 27.2 | 19.9 | 0.004 |
| 2nd QR | 24.4 | 27.4 | 26.7 | 21.3 | 23.5 | 28.3 | 24.7 | 21.7 | ||
| 3rd QR | 26.4 | 25.3 | 24.6 | 26.1 | 23 | 24.4 | 24.8 | 28.2 | ||
| 4th QR | 29.5 | 22.5 | 24.9 | 30.6 | 24.1 | 22.6 | 23.3 | 30.2 | ||
| Chemotherapy | ||||||||||
| None | 70.8 | 76 | 64.7 | 47.8 | 0.0001 | 46.6 | 76.8 | 67.4 | 52.8 | 0.0001 |
| Neoadjuvant Only | 5 | 4.9 | 6.1 | 4.4 | <5 | 4.5 | 4 | 6.5 | ||
| Adjuvant Only | 9.5 | 2.4 | 11.6 | 25.8 | 25.4 | 4.1 | 8.8 | 17.2 | ||
| Treatment Only | 8.5 | 13.8 | 10 | 9.2 | 10 | 10.8 | 13.9 | 10.6 | ||
| Neoadjuvant and Adjuvant | <5 | <5 | 2.5 | 1.9 | <5 | 0.3 | <5 | 1.7 | ||
| Neoadjuvant or Adjuvant then Treatment | <5 | <5 | 5.1 | 8.4 | 8.5 | 2.6 | <5 | 8.8 | ||
| Continuous | <5 | <5 | <5 | 2.5 | 3.7 | 0.9 | <5 | 2.4 | ||
*
Cell sizes that could be derived as a cell size <11 were suppressed in accordance with the SEER-Medicare Data Use agreement. Those cells are reported as < 5%. In Situ cancer was rare at cystectomy, and for reporting in accordance with SEER-Medicare Data Use agreements has been combined with the no cancer group.